Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences

- No satisfactory treatment are current available for malignant mesothelioma patients.
- Several research lines are being pursued, among them, immunotherapy seems the most one promising approach in mesothelioma.
- The potential therapeutic role of targeting immune checkpoints used alone or in combination for mesothelioma is discussed.

Treatment with immune-checkpoint blocking monoclonal antibody (mAb) is demonstrating a significant efficacy in different tumor types.Here, we discuss the impact of this promising approach in malignant mesothelioma (MM), a still dreadful disease in which medical treatment has been set on platinum based chemotherapy for decades with unsatisfactory results.